Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Brendan Arsenault"'
Autor:
Joi Dunbar, Margaret A. Read, Joseph D. Manna, Alexander Constan, Alfredo C. Castro, Sherri Smith, Gordon Loewen, John Lee, Somarajan J. Nair, Jennifer Hoyt, Martin R. Tremblay, Julian Adams, Jeanne A. Ferguson, Jens Sydor, Veronica Campbell, Matthew Campbell, Karen McGovern, Brendan Arsenault, Marisa O. Peluso, Jylle Nevejans, Vito J. Palombella, Nigel Whitebread, Grogan Michael John, Kerrie Faia, John Soglia, Bennett Carter
Publikováno v:
Xenobiotica. 43:875-885
1. IPI-926 is a novel semisynthetic cyclopamine derivative that is a potent and selective Smoothened inhibitor that blocks the hedgehog signal transduction pathway. 2. The in vivo clearance of IPI-926 is low in mouse and dog and moderate in monkey. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50620a2c18fbef25785c49cf6a0c9deb
https://doi.org/10.3109/00498254.2013.780671
https://doi.org/10.3109/00498254.2013.780671
Autor:
John Lee, Roger H. Pak, Louis Grenier, Vince Ammoscato, Michael Curtis, Kaiming Li, John Henderson, Matthew Campbell, Denise Mayes, Jason Kropp, Natalie Goltz, Bennett Carter, Johan Sebastian Basuki, Bradley Maurer, Gary Baker, James R. Wright, David Rusch, Rebecca Ahn, Brian C. Austad, Kris Depew, Joseph Helble, Jie Ge, Jason J. Piotrowski, Marlene R. Booth, Julian Adams, Mark Douglas, Steven G. Wong, Laila Kott, James R. Porter, Geoff E. Sylvester, Dumitru Ionescu, Jennifer R. Porter, Brendan Arsenault
Publikováno v:
Drug Development Research. 71:429-438
IPI-504 (retaspimycin hydrochloride) is an Hsp90 inhibitor that is the subject of multiple clinical trials for the treatment of cancer. IPI-504 is an aqueous soluble (>200 mg/ml) hydroquinone hydrochloride salt of 17-(allylamino)-17-demethoxygeldanam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1542e76e86b5ffd5bfe160834ae9e695
https://doi.org/10.1002/ddr.20383
https://doi.org/10.1002/ddr.20383